A Study of the Safety and Pharmacokinetics of MINT1526A, Administered Intravenously As a Single Agent and in Combination With Bevacizumab to Patients With Advanced Solid Tumors

Part of paid clinical trials in Encinitas, California.

Sponsor
Genentech, Inc.
Study ID
NCT01139723
Phase
PHASE1
Status
Completed

Conditions

  • Solid Cancers

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MINT1526A — DRUG
    Intravenous escalating dose
  • bevacizumab — DRUG
    Intravenous repeating dose

Study Details

This is a Phase I, first-in-human, open label, dose-escalation study of MINT1526A administered alone and in combination with bevacizumab by IV infusion every 3 weeks to patients with advanced solid tumors for whom standard therapy either does not exist or has proven to be ineffective or intolerable.

Key Dates

First listed
Jun 8, 2010
Start date
Jun 30, 2010
Status verified
Nov 2016
Primary completion
Aug 31, 2014
Completion
Aug 31, 2014

Study Design

Enrollment
54 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: A
  • Experimental: B

Primary Outcome Measure

Incidence and nature of dose-limiting toxicities (DLTs) [ Time Frame: Days 1 to 21 of cycle 1 ]

Locations (3)

FacilityCityStateZIPSite coordinators
-EncinitasCalifornia92008-
-Los AngelesCalifornia90095-
-AuroraColorado80045-

Related Studies